Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Modulation of anti-tumour immunity using CDK4/6 inhibitors

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.18
Views: 974

Dr Shom Goel - Dana-Farber Cancer Institute, Boston, USA

Dr Shom Goel speaks to ecancer at SABCS 2018 about the modulation of anti-tumour immunity using CDK4/6 inhibitors.

He explains that CDK4/6 inhibitors not only stop cancer cells from dividing but also aid the immune system by increasing the level the cell presents antigen and making them more visible to the immune system.

He also reports the effect to the actual immune cells as, although some of the effects can decrease the activity of T lymphocytes, other effects can cause an increase in activity, with Dr Goel believing the information gathered so far shows the positives to outweigh the negatives.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation